Franco Valle

Franco Valle, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Eidos Therapeutics, Inc. and Biomea Fusion, Inc. The record holds 28 filings, for trades running from 2 March 2020 to 30 November 2024.

In open-market terms, that means 3 purchases worth €158k on one side and 10 sales worth €1.6M on the other. Netting one side against the other leaves €1.4M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 7 share grants and 8 option exercises. In 2024 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €52k. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The latest filing, published on 2 December 2024, reports a share grant of €2,884 in Biomea Fusion, Inc. The most recent open-market purchase was published on 12 June 2024, 863 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.